R. R. Zielinski, A. A. Azad, K. N. Chi, and S. Tyldesley, “Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer”, CUAJ, vol. 8, no. 7-8, pp. e520–3, Aug. 2014.